Comprehensive analysis of Edelweiss Nifty Alpha Low Volatility 30 Index Fund-Dir (44837) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Edelweiss Asset Mgt Ltd
The investment objective of the scheme is to provide returns before expenses that closely correspond to the total returns of the Nifty Alpha Low Volatility 30 Index, subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
Low Expense Ratio
Equity Focused
New Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Market exposure level
Outperformance vs benchmark
Fund management costs
Recent performance momentum
Risk-adjusted returns
Fund manager experience
Assets under management
Historical performance consistency
This fund has underperformed its benchmark by 0.64% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| ICICI Bank Ltd | Banks | 4.62% |
| HDFC Bank Ltd | Banks | 4.49% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 4.36% |
| ITC Ltd | Tobacco Products | 4.19% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 4.15% |
| HDFC Life Insurance Company Ltd | Insurance | 3.96% |
| Bharti Airtel Ltd | Telecomm-Service | 3.88% |
| Britannia Industries Ltd | FMCG | 3.87% |
| Divis Laboratories Ltd | Pharmaceuticals | 3.75% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 3.71% |
Compare against Index Fund category average
This comparison shows how the fund performs relative to the Index Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Index Fund category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (IDCW) | ₹1230.12 | -1.03% | 4.26% | 8.39% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (G) | ₹1230.12 | -1.03% | 4.26% | 8.39% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (G) | ₹1225.70 | -1.07% | 4.18% | 8.23% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (IDCW) | ₹1225.68 | -1.07% | 4.18% | 8.23% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (G) | ₹1208.94 | 1.16% | 4.38% | 8.21% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (IDCW | ₹1208.94 | 1.16% | 4.38% | 8.21% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (IDCW) | ₹1204.58 | 1.13% | 4.31% | 8.05% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (G) | ₹1204.56 | 1.13% | 4.31% | 8.05% |
| HDFC BSE Sensex Index Fund - Direct | ₹766.86 | 0.30% | 11.07% | -1.48% |
| HDFC BSE Sensex Index Fund - Regular | ₹748.57 | 0.26% | 10.99% | -1.63% |
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.